On October 7, 2021 ProfoundBio reported that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Research (AACR) (Free AACR Whitepaper), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) (Press release, ProfoundBio, OCT 7, 2021, View Source [SID1234590959]). The presentation is entitled, "Novel Hydrophilic Drug Linkers Enable Exatecan-based Antibody-Drug Conjugates with Promising Physiochemical Properties and In Vivo Activity."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our platform enables us to develop ADCs that could otherwise not even be considered for development. By optimizing physiochemical properties, our platform enables the use of hydrophobic payloads at a drug to antibody ratio (DAR) up to 8, and potentially higher, while maintaining similar pharmacokinetics to unconjugated mAb, robust anti-tumor activity, and an acceptable safety profile," said Baiteng Zhao, PhD, Chief Executive Officer at ProfoundBio. "This technology has the potential to usher in a new generation of ADCs that will meaningfully help patients who have cancer."